Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Future Oncol. 2013 Aug;9(8):1133-44. doi: 10.2217/fon.13.65.
In 2004, the chemotherapy agent docetaxel was approved for the treatment of metastatic prostate cancer. Although it has taken almost a decade, significant new advances have been made in this area, including the clinical development of modern hormonal therapies, such as abiraterone and enzalutamide, and immunotherapies, such as sipuleucel-T, all of which have improved survival in metastatic prostate cancer. These agents have not only provided new therapeutic options for patients with advanced disease, they have also spurred research in both androgen receptor-targeting therapy and immunotherapy. Future trials will focus on the optimal sequence of these and other emerging therapies, with the aim of using these treatments earlier in the disease course (including the adjuvant setting) to enhance clinical benefit and potentially increase the cure rate for prostate cancer.
2004 年，化疗药物多西他赛被批准用于治疗转移性前列腺癌。尽管已经过去了近十年，但在这一领域取得了重大的新进展，包括现代激素治疗的临床开发，如阿比特龙和恩杂鲁胺，以及免疫疗法，如 sipuleucel-T，所有这些都提高了转移性前列腺癌的生存率。这些药物不仅为晚期疾病患者提供了新的治疗选择，还促进了针对雄激素受体靶向治疗和免疫治疗的研究。未来的试验将集中在这些药物和其他新兴疗法的最佳应用顺序上，目的是在疾病过程中更早地使用这些治疗方法（包括辅助治疗），以提高临床获益，并有可能提高前列腺癌的治愈率。
